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Abstract
Background
Several studies have shown associations between blood lipid levels and the risk of atrial
fibrillation (AF). To test the potential effect of blood lipids with AF risk, we assessed whether
previously developed lipid gene scores, used as instrumental variables, are associated with
the incidence of AF in 7 large cohorts.
Methods
We analyzed 64,901 individuals of European ancestry without previous AF at baseline and
with lipid gene scores. Lipid-specific gene scores, based on loci significantly associated
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with lipid levels, were calculated. Additionally, non-pleiotropic gene scores for high-density
lipoprotein cholesterol (HDLc) and low-density lipoprotein cholesterol (LDLc) were calcu-
lated using SNPs that were only associated with the specific lipid fraction. Cox models were
used to estimate the hazard ratio (HR) and 95% confidence intervals (CI) of AF per 1-stan-
dard deviation (SD) increase of each lipid gene score.
Results
During a mean follow-up of 12.0 years, 5434 (8.4%) incident AF cases were identified. After
meta-analysis, the HDLc, LDLc, total cholesterol, and triglyceride gene scores were not
associated with incidence of AF. Multivariable-adjusted HR (95% CI) were 1.01 (0.98–
1.03); 0.98 (0.96–1.01); 0.98 (0.95–1.02); 0.99 (0.97–1.02), respectively. Similarly, non-
pleiotropic HDLc and LDLc gene scores showed no association with incident AF: HR (95%
CI) = 1.00 (0.97–1.03); 1.01 (0.99–1.04).
Conclusions
In this large cohort study of individuals of European ancestry, gene scores for lipid fractions
were not associated with incident AF.
Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and is associated
with increased risks of heart failure, stroke, and cardiovascular death,[1] including a 9-fold
higher risk of mortality within the first four months after AF, compared to those without AF.
[2] Some major risk factors for AF include age, white race, obesity, heart failure, coronary heart
disease, left ventricular hypertrophy, and hypertension, along with certain lifestyle factors.[3–
5] These predictors are similar to the risk factors for cardiovascular disease (CVD) in general,
which often precede an AF diagnosis.[1]
High levels of total cholesterol, triglycerides and low-density lipoprotein cholesterol (LDLc)
and low levels of high-density lipoprotein cholesterol (HDLc) have long been associated with
CVD. The associations between lipid levels with incident AF have been inconsistent across
observational studies.[6–11] However, several cohorts have reported associations between
lower levels of LDLc and total cholesterol with incident AF, while others have reported no asso-
ciation.[6,8–11] In particular, the Atherosclerosis Risk in Communities (ARIC) study and the
Women's Health Study both found inverse associations between LDLc and incident AF; hazard
ratio (HR) and 95% confidence interval (CI) per 1 standard deviation increase = 0.90 (0.85–
0.96) and HR (95% CI) comparing the top quintile to bottom quintile = 0.72 (0.56–0.92),
respectively.[6,10] Table 1 depicts the previously reported associations between AF and blood
lipids from observational cohorts, including 3 of the cohorts evaluated in the present analysis.
Reasons for this inverse association are not clear, and it is not possible to determine if choles-
terol has a direct causal effect on AF risk in observational studies.
One approach to evaluate whether lipid levels are causally associated with AF risk is to per-
form a Mendelian randomization analysis, which uses genetic variants as an instrumental vari-
able in determining association with an outcome independent of confounders.[12] Several
genome-wide association studies (GWAS) have identified genes associated with blood lipopro-
tein levels, [13–15] including a meta-analysis of> 100,000 individuals of European ancestry by
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Teslovich and colleagues that identified 95 loci significantly associated with lipid phenotypes.
[16] Data from that analysis have been used to create phenotype-specific lipid gene scores to
estimate the effect of lipid genes on lipid levels.[17,18] We used these lipid gene scores as
instrumental variables to examine the association between lipid levels and incident AF in 7 US
and European prospective cohort studies participating in the AF Genetics (AFGen) consor-
tium.[19]
Methods
Study Cohorts
Data from the following 7 cohorts was included: the Age, Gene/Environment Susceptibility—
Reykjavik study (AGES), the Atherosclerosis Risk in Communities (ARIC) study, the Framing-
ham Heart Study (FHS), the Malmö Diet and Cancer study (MDCS), 2 cohorts from the Rot-
terdam Study (RS-I and RS-II), and the Women's Genome Health Study (WGHS). A brief
description of each participating cohort is provided below, with more information in the S1
File. Each cohort determined which examination to select as baseline, based on the availability
of genetic and lipid data, covariates, date of DNA draw, and adequate follow-up time for the
development of AF. Our analysis includes consenting participants with complete genetic data
who were of white race. Participants were excluded if they had previous AF at baseline, had
missing information of AF status at baseline, and those with missing covariates of interest.
After applying exclusion criteria, the entire sample included 64,901 participants. Institutional
Review Boards at the participating institutions approved the individual studies and study par-
ticipants provided written informed consent.
Age, Gene/Environment Susceptibility Reykjavik Study. The original Reykjavik Study,
conducted between 1967 and 1996, included ~ 19,000 men and women living in the greater
Reykjavik area, born between 1907 and 1935.[20] Survivors of this study were invited to be
part of AGES, which recruited 5764 men and women in 2002–2007, considered baseline years
for this study. Of the survivors, 2953 met inclusion criteria and were considered for this analy-
sis. Participant follow-up for this analysis was through 2012.
The AGES study was approved by the National Bioethics Committee in Iceland (VSN 00–
063) as well as the Institutional Review Board of the Intramural Research Program of the
National Institute on Ageing and the Data Protection Authority in Iceland.
Table 1. Previously discoveredmultivariable-adjusted cohort-specific Hazard Ratios and 95%Confidence Intervals of the risk of atrial fibrillation
associated with blood lipids. Associations are per 1 standard deviation increase unless noted. ARIC, Atherosclerosis Risk in Communities; FHS, Framing-
ham Heart Study; WHS, Women's Health Study; MESA, Multi-Ethnic Study of Atherosclerosis; CHS, Cardiovascular Health Study.
Cohort Total Cholesterol HDLc LDLc Triglycerides
ARIC [6] 0.89 (0.84–0.95) 0.97 (0.91–1.04) 0.90 (0.85–0.96) 1.00 (0.96–1.04)
FHS [7] 0.99 (0.87–1.12) 0.93 (0.81–1.08) 0.95 (0.82–1.09) 1.15 (1.02–1.30)
WHS[10] 0.76 (0.59–0.98) a 1.07 (0.83–1.39) a 0.72 (0.56–0.92) a 0.83 (0.63–1.09) a
MESA [7] 1.13 (0.98–1.30) 0.85 (0.72–1.00) 1.15 (0.99–1.35) 1.16 (1.02–1.33)
CHS [9] 0.86 (0.76–0.98)
Watanabe et al.[8] 0.93 (0.85–1.02) b 0.92 (0.88–0.96) b 0.98 (0.96–1.00) b
Iguchi et al.[11] 0.75 (0.58–0.96) c
aComparing quintile 5 to quintile 1
bPer 10 mg/dL increase
cOdds ratio of total cholesterol > = 220
doi:10.1371/journal.pone.0151932.t001
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Atherosclerosis Risk in Communities study. The ARIC study is a prospective cohort
study of 15,792 men and women aged 45–64, recruited from four communities in the US
(Washington County, MD; suburbs of Minneapolis, MN; Jackson, MS; Forsyth County, NC) in
1987–89.[21] Participants were mostly white in the Washington County and Minneapolis cen-
ters, only African-American in the Jackson center, and included both races in Forsyth County.
After the initial assessment, study participants were examined four additional times (1990–92,
1993–95, 1996–98, 2011–13). Our analysis includes 8849 ARIC white participants that met
inclusion criteria at baseline (1987–89). Follow-up for this analysis was through 2009. The Uni-
versity of Minnesota Institutional Review Board approved the present ARIC study, and all par-
ticipants enlisted in the ARIC study have given their written informed consent.
Framingham Heart Study. In 1971–1975, the FHS Offspring cohort enrolled 5124 pre-
dominantly white men and women, offspring (and their spouses) from the Original FHS
cohort (1948–1950) with follow-up examinations every 4 to 8 years. [22] The current analysis
included 4126 participants of the FHS Offspring cohort that were free of AF, and were followed
through 2011. The FHS was approved by the Institutional Review board of Boston University
Medical center, and all participants enlisted in this study have given their written informed
consent.
Malmö Diet and Cancer Study. The Malmö Diet and Cancer Study is a prospective study
and recruited 45-64-year-old men and women in 1991–96, living in Malmö, Sweden, a city
which then had a population of 230,000 inhabitants.[23] Baseline examinations were per-
formed in 30,447 participants. For this study, 28,218 participants met inclusion criteria and
were considered for this analysis. Follow-up was through 2009. MDCS was approved by the
ethics committee of Lund University, Sweden and informed written consent was obtained
from all participants in the study.
Rotterdam Study. The RS, a prospective population-based study aimed to assess the
determinants of chronic conditions in the elderly, started in 1989 in Rotterdam.[24] At base-
line, 7983 participants were included and in 2000, an additional 3011 participants were
included. Participants have been continuously followed and were reexamined approximately
every 4–5 years. The present analysis included participants that met inclusion criteria: 4560
study participants examined in 1989–93, and 1689 examined in 2000–2001. Follow-up for both
cohorts was through 2011. RS was approved by the medical ethics committee of Erasmus Uni-
versity, and written consent was obtained from all participants.
Women's Genome Health Study. WGHS is an ongoing prospective cohort GWAS that
derives from the NIH-funded Women’s Health Study (WHS) and includes more than 25,000
initially healthy women aged 45 years and older, who have already been followed since 1992–
95 for the development of common disorders such as CVD.[25] Our analysis includes 14,056
eligible females that were followed through 2011. Informed consent was obtained from all par-
ticipants in the WGHS, and the Brigham and Women's Hospital Institutional Review Board
for Human Subjects Research approved the study protocol.
Ascertainment of atrial fibrillation
AF cases in all cohorts were ascertained using a variety of cohort-specific methods, including
study physician-adjudicated cases, study electrocardiograms, hospitalization discharge diagno-
sis codes, or death certificates (ICD-9-CM 427.3, 427.31 or 427.32, or ICD-10 I48 in any posi-
tion).[1,3,9,26] Further details of AF ascertainment in each cohort are available in the S1 File.
In this analysis, the incidence date of AF was defined as the date of the first ECG showing AF,
date of diagnosis within the medical record, the first hospital discharge coded as AF, or when
AF was listed as a cause of death, whichever occurred earlier.
Lipid Gene Scores and Atrial Fibrillation
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Assessment of lipid gene scores
In all studies, genotyping was performed on baseline samples. Genotyping and quality control
methods are described elsewhere for each study, and the S1 File contain a brief overview for
genotyping information (Table A in S1 File). [19,27–29] Of note, MDCS had slightly different
genotyping methods, and thus their lipid gene scores are marginally lower compared to the
other cohorts.[27] MDCS did not have available SNPs for total cholesterol, and any other dif-
ferences in scores are noted in Table B in S1 File.
To create the lipid gene scores, we used SNPs identified in the Teslovich et al. GWAS. [16]
Separate effect size-based gene scores were created for each lipid phenotype (HDLc, LDLc,
total cholesterol and triglycerides). More detailed creation of the scores is described elsewhere.
[17] Briefly, for each individual, the number of unfavorable alleles (0, 1 or 2) for each SNP was
multiplied by the absolute value of the additive effect size published in the Teslovich et al.
GWAS.[16] The product was summed across each individual SNP and then rescaled by divid-
ing that sum by the average effect size. Lastly, cohorts divided their phenotype-specific gene
score by 1 standard deviation. A second gene score was created in the same manner for HDLc
and LDLc including only SNPs exclusively associated with each specific cholesterol fraction.
[18] This non-pleiotropic score was then used to assess potential causal effects of each fraction
without including indirect effects through other cholesterol fractions, as recently described.
[18] The final scores included 47 SNPs for HDLc, 37 SNPs for LDLc, 52 SNPs for total choles-
terol, and 32 SNPs for triglycerides (listed in Table B in S1 File). The final scores for MDCS
included 41 SNPs for HDLc, 32 SNPs for LDLc, and 27 SNPs for triglycerides. The non-pleio-
tropic score for HDLc included 14 SNPs and LDLc included 13 SNPs.
Measurement of other covariates
All study cohorts collected information on anthropometric measures, blood pressure, blood
lipids, fasting glucose, as well as assessment of prior cardiovascular disease and medication use.
Details on measurement methods are provided in the S1File. Protocols for variable ascertain-
ment and definitions of cardiovascular risk factors were comparable across cohorts.
Statistical analysis
We estimated the association of a 1 standard deviation (cohort-specific) increase in each lipid
gene score with the incidence of AF using Cox proportional hazards models with time to AF as
the main outcome variable. Follow-up time was defined as the time elapsed between baseline
and date of AF incidence, death, lost to follow-up or until the end of available data, whichever
came earlier. Models were adjusted for baseline covariates including age, sex, study site (for
ARIC), cohort (for FHS), education (high school graduate vs. not; N/A in FHS), height (contin-
uous), smoking (current vs. not), body mass index (continuous), systolic blood pressure (con-
tinuous), diastolic blood pressure (continuous), use of antihypertensive medications, diabetes
mellitus (dichotomous), electrocardiograph left ventricular hypertrophy, previous stroke, pre-
vious heart failure and previous coronary heart disease. An additional model was performed
also adjusting for continuous lipid levels (N/A in MDCS) and lipid medication use. Cohorts
missing information on lipid levels, left ventricular hypertrophy, previous stroke, previous
heart failure, or previous coronary heart disease only adjusted for the available variables. With
65,000 participants, 8% having AF, a trait variance of 5% explained by lipid genes, and an odds
ratio of 0.80 for the association between blood lipids and AF incidence, this instrument had
88% power to detect an association between lipid gene scores and AF in this Mendelian ran-
domization study.[30] Finally, results were meta-analyzed for each specific lipid gene score
Lipid Gene Scores and Atrial Fibrillation
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using a fixed-effects model. All statistical analyses were performed with SAS v 9.2 (SAS Inc,
Cary, NC) or STATA (v.13, STATA Corp).
Results
Selected baseline characteristics for cohort participants are shown in Table 2. There were a
total of 64,901 participants in all cohorts combined. The cohorts had a higher prevalence of
women than men. The participants’mean ages at baseline ranged from 54 years in ARIC and
WGHS to 76 years in AGES. The gene scores were similar across cohorts, with the MDCS
score being slightly lower, due to unavailability of some components of the score. During a
mean follow-up of 12 years, 5434 (8.4%) incident AF cases were identified. Cumulative risk
ranged between 4% in WGHS and 14% in AGES, ARIC, and FHS. The study-specific risk of
incident AF cases depended on 1) age at baseline, with older cohorts having a higher incidence;
Table 2. Baseline characteristics of study participants by cohort. Values correspond to N (%) or mean (standard deviation). The standard deviation of
each gene score in each cohort is 1 due to the method of standardization used.—AGES, indicates the Age, Gene/Environment Susceptibility—Reykjavik
study; ARIC, Atherosclerosis Risk in Communities; FHS, Framingham Heart Study; MDCS, Malmö Diet and Cancer study; RS, Rotterdam Study; WGHS,
Women's Genome Health Study; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDLc, high density lipoprotein cholesterol; LDLc, low density
lipoprotein cholesterol; LVH, left ventricular hypertrophy; NA, not available, * not fasting.
AGES
(n = 2953)
ARIC
(n = 8849)
FHS
(n = 4126)
MDCS
(n = 28,218)
RS-I
(n = 4560)
RS-II
(n = 1689)
WGHS
(n = 14506)
Age, years 76 (5) 54 (6) 64 (13) 58 (8) 68 (8) 65 (8) 54 (7)
Men 1341 (42%) 4117 (47%) 1795 (44%) 11135 (40%) 1860 (41%) 774 (46%) 0
Height, cm 167 (9) 169 (10) 166 (10) 169 (9) 167 (9) 169 (9) 164 (6)
Current cigarette smoking 404 (13%) 2151 (24%) 613 (15%) 8076 (29%) 1074 (24%) 375 (22%) 1653 (11%)
Body mass index, kg/m² 27 (4) 27 (5) 28 (5) 26 (4) 26 (4) 27 (4) 26 (5)
SBP, mmHg 143 (20) 118 (17) 130 (20) 141 (20) 139 (22) 143 (21) 124 (14)
DBP, mmHg 74 (10) 72 (10) 74 (10) 86 (10) 74 (11) 79 (11) 77 (9)
Hypertensive medication 2036 (64%) 2184 (25%) 1453 (35%) 4786 (17%) 1903 (42%) 452 (27%) 1886 (13%)
Diabetes mellitus 366 (11%) 691 (8%) 327 (8%) 810 (2.9) 437 (10%) 179 (11%) 320 (2%)
HDLc < 40 mg/dL 261 (8%) 2510 (28%) 899 (23%) NA 4421 (97%)* 1656 (98%)* 2342 (16%)
LDLc 160mg/dL 846 (27%) 2240 (25%) 450 (14%) NA NA NA 2096 (14%)
Total cholesterol,  240
mg/dL
919 (28%) 2070 (23%) 620 (16%) NA 2 (0%)* 0 (0%) 3219 (22%)
Triglycerides,  200 mg/dL 180 (6%) 1191 (13%) 665 (18%) NA NA 1 (0%) 2317 (16%)
LVH NA 74 (1%) 41 (1%) NA 174 (4%) 36 (2%) NA
Previous stroke NA 125 (2%) 96 (2%) 290 (1%) 102 (2%) 57 (3%) NA
Previous heart failure 97 (3%) 309 (3%) 53 (1%) 57 (0.2%) 103 (2%) 37 (2%) NA
Previous coronary heart
disease
NA 418 (5%) 284 (7%) 538 (2%) 579 (13%) 85 (5%) NA
Lipid lowering medication
use
724 (23%) 295 (3%) 625 (15%) 778 (3%) 101 (2%) 203 (12%) 513 (4%)
HDLc gene score 9.1 9.3 10.1 8.6 10.0 10.0 9.9
LDLc gene score 9.7 9.5 9.5 8.4 9.4 9.4 9.4
Total cholesterol gene
score
12.7 12.7 12.8 NA 12.6 12.6 12.3
Triglyceride gene score 9.4 9.6 9.7 8.4 9.6 9.5 9.4
# Atrial ﬁbrillation cases 422 (14%) 1207 (14%) 565 (14%) 2087 (7%) 571 (13%) 78 (5%) 504 (4%)
Mean follow-up time, years
(SD)
7.3 (3) 18.6 (5) 9.7 (4) 13.8 (4) 13.2 (6) 6.6 (1) 15.6 (3)
Baseline years 2002–2007 1987–1989 1987–2007 1991–96 1989–93 2000–01 1992–1995
End of follow-up 2012 2009 2011 2009 2011 2011 2011
doi:10.1371/journal.pone.0151932.t002
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2) the amount of follow-up time in the study, since more cases would be captured in a longer
time frame; and 3) the gender of the participants, with women having a lower risk of AF when
compared to men. Thus, higher cumulative risk of AF was observed in studies with the long
follow-up, like ARIC, and older age at baseline, like AGES, while studies recruiting younger
participants, WGHS, and with shorter follow-up (Rotterdam Study-II) reported lower risks.
After adjustment for potential confounders and intermediates there was no significant asso-
ciation between any of the lipid gene scores with incident AF in the individual cohorts
(Table 3). When models were adjusted for lipid levels and lipid medication use, there was little
change in the results, and associations remained similar across all cohorts. A meta-analysis of
findings across all cohorts showed no significant association between any of the lipid gene
scores with incident AF (Fig 1). HR and 95% CI for AF with a 1-SD increase in HDLc gene
score was 1.01 (0.98–1.03); for LDLc, 0.98 (0.96–1.01); total cholesterol, 0.98 (0.95–1.02) and
triglycerides, 0.99 (0.97–1.02). No causal estimate for the effect of concentrations of blood lip-
ids on AF risk was calculated due to the null results.
Narrowing the HDLc and LDLc gene scores to non-pleiotropic genes did not result in any
significant associations between incident AF and an increase in scores (Table 4). Fig 2 shows
the meta-analysis for the non-pleiotropic scores. Overall, the association [HR (95% CI)]
between HDLc and AF was 1.00 (0.97–1.03) and for LDLc 1.01 (0.99–1.04).
Discussion
In our prospective, multi-cohort study including 64,901 white participants from 7 large
cohorts, with 5434 AF cases, we found a consistent lack of association between the lipid genetic
scores and incidence of AF. Similarly, narrowing the genetic score to genes more specific for
HDLc or LDLc levels showed no independent associations between non-pleiotropic genetic
scores and risk for AF. These associations were adjusted for lifestyle factors, clinical factors,
and cardiovascular disease. The results of our Mendelian randomization approach, in which
Table 3. Multivariable adjusted Hazard Ratios (95% confidence interval) of Atrial Fibrillation of a 1 Standard Deviation Increase in Lipid Gene
Score, by Cohort. HR, Hazard Ratio; CI, Confidence interval; NA, not available. -AGES, indicates the Age, Gene/Environment Susceptibility—Reykjavik
study; ARIC, Atherosclerosis Risk in Communities; FHS, Framingham Heart Study; MDCS, Malmö Diet and Cancer study; RS, Rotterdam Study; WGHS,
Women's Genome Health Study. Model 1: Cox proportional hazard model adjusted for age, sex and study center, if appropriate. Model 2: Model 1 + educa-
tion, height, smoking status, body mass index, systolic blood pressure, diastolic blood pressure, use of antihypertensive medication, diabetes, left ventricular
hypertrophy, previous stroke, previous coronary heart disease and previous heart failure. Model 3: Model 2 + adjusted for continuous lipid levels and lipid
medication use.
AGES ARIC FHS MDCS RS-I RS-II WGHS
HDLc gene score
Model 1: HR (95% CI) 1.04 (0.94–1.14) 1.01 (0.95–1.06) 1.06(0.98–1.15) 0.97 (0.93–1.01) 0.99 (0.92–1.07) 0.90 (0.74–1.10) 1.08 (0.99–1.18)
Model 2: HR (95% CI) 1.04 (0.95–1.15) 1.02 (0.96–1.07) 1.08(0.99–1.17) 0.98 (0.94–1.02) 0.98 (0.91–1.05) 0.90 (0.74–1.11) 1.08 (0.99–1.18)
Model 3: HR (95% CI) 1.02 (0.92–1.13) 1.02 (0.96–1.08) 1.05(0.94–1.16) NA 0.98 (0.91–1.06) 0.92 (0.74–1.13) 1.10 (1.01–1.21)
LDLc gene score
Model 1: HR (95% CI) 1.03 (0.93–1.14) 0.97 (0.91–1.02) 1.00(0.91–1.09) 0.97 (0.93–1.02) 0.92 (0.85–1.00) 1.07 (0.86–1.34) 1.04 (0.95–1.13)
Model 2: HR (95% CI) 1.03 (0.94–1.14) 0.97 (0.91–1.02) 1.00(0.91–1.09) 0.97 (0.93–1.01) 0.93 (0.85–1.01) 1.13 (0.90–1.42) 1.04 (0.96–1.14)
Model 3: HR (95% CI) 1.04 (0.94–1.15) 0.97 (0.91–1.02) 1.02(0.91–1.15) NA 0.95 (0.87–1.04) 1.19 (0.93–1.51) 1.08 (0.98–1.18)
Total cholesterol gene score
Model 1: HR (95% CI) 1.04 (0.94–1.14) 0.97 (0.91–1.02) 0.96(0.88–1.05) NA 0.92 (0.85–1.00) 1.01 (0.81–1.26) 1.04 (0.95–1.13)
Model 2: HR (95% CI) 1.04 (0.95–1.15) 0.97 (0.91–1.02) 0.96(0.88–1.05) NA 0.93 (0.86–1.01) 1.05 (0.84–1.31) 1.04 (0.96–1.14)
Model 3: HR (95% CI) 1.06 (0.96–1.17) 0.97 (0.91–1.02) 0.97(0.87–1.09) NA 0.96 (0.88–1.04) 1.09 (0.86–1.37) 1.07 (0.98–1.17)
Triglyceride gene score
Model 1: HR (95% CI) 1.05 (0.96–1.16) 0.99 (0.93–1.04) 0.99(0.91–1.08) 0.99 (0.95–1.04) 0.91 (0.83–0.98) 0.89 (0.72–1.11) 1.06 (0.98–1.16)
Model 2: HR (95% CI) 1.06 (0.96–1.16) 0.99 (0.94–1.05) 0.99(0.91–1.08) 1.00 (0.96–1.05) 0.90 (0.83–0.98) 0.88 (0.71–1.11) 1.06 (0.97–1.16)
Model 3: HR (95% CI) 1.06 (0.96–1.18) 0.99 (0.94–1.05) 0.98(0.88–1.09) NA 0.91 (0.84–1.00) 0.91 (0.72–1.15) 1.07 (0.98–1.17)
doi:10.1371/journal.pone.0151932.t003
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we used lipid gene scores as instrumental variables, do not support a casual association between
blood lipid levels and risk of AF, assuming that these genetic variants could only cause AF
through mediating effects of these lipids.
The paradoxical association of LDLc with incident AF, though inconsistent, has been seen
in a number of studies, and remains unexplained (Table 1).[6,8–11] Some proposed mecha-
nisms include cholesterol-mediated changes in the distribution of atrial ion channels,[31]
Fig 1. Meta-analysis of the association of lipid gene scores, and atrial fibrillation. Association is adjusted for age, sex, center, education, height,
smoking status, body mass index, systolic blood pressure, diastolic blood pressure, use of antihypertensive medication, diabetes, left ventricular
hypertrophy, previous stroke, previous coronary heart disease, and previous heart failure
doi:10.1371/journal.pone.0151932.g001
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unmeasured confounding by hyperthyroidism,[32] malnutrition, fluid imbalances, or by other
confounders including natriuretic peptides.[7] A recent analysis of the Women’s Health Study
also reported an inverse association between blood LDLc and AF risk, and this association was
mainly driven by cholesterol-poor small LDL particles and small VLDL particles. No associa-
tion was observed between cholesterol-rich LDL particles and AF, suggesting that risk for AF is
probably not mediated through a direct effect of cholesterol.[10] If small LDL particles are
truly responsible for the inverse association of LDL cholesterol and AF, one explanation for the
absence of association between LDLc gene scores and AF in our study is that the cholesterol
genes that have been discovered and included in this lipid gene score could be associated with
the cholesterol component of lipoprotein particles. This potential explanation may be explored
further as more specific genetic variants affecting lipoprotein particle size are discovered.
The associations between HDLc, triglycerides and incident AF have been inconsistent, with
some studies reporting an increased risk of AF in those with low HDLc levels or high triglycer-
ide levels, and other studies finding no association between those lipid levels and AF. [6–11]
These inconsistencies remain unexplained and our findings would suggest that associations
between AF and low HDLc are not mediated by known polymorphisms associated with HDL
levels. It is possible that the associations observed in some studies may be due to residual con-
founding by other cardiovascular or metabolic risk factors, since low HDLc and high triglycer-
ides can be part of the metabolic syndrome, which has also been associated with AF risk. [33]
Strengths and limitations
A few limitations should be noted. First, the studied cohorts recruited different populations
across diverse settings using a variety of methods for measurement of covariates and ascertain-
ment of AF. Despite these differences, no evidence of heterogeneity was observed in the meta-
analysis of cohort-specific results. Second, some cohorts mostly relied on electrocardiograms
performed at study visits and hospital discharge codes, leading to the potential for misclassifi-
cation of AF, though validation in ARIC and other populations have demonstrated adequate
specificity with positive predictive value of ~90%.[3,9] Third, asymptomatic AF and AF man-
aged exclusively in an outpatient setting were not consistently identified. Fourth, some SNPs in
the GWAS score were imputed, and the genes scores only explain a portion of the variation
seen in lipid levels. [17] For example, in ARIC, Lutsey et al. found that each phenotype-specific
gene score explained 1.6% of the variance in HDLc levels, 6% of the variance in LDLc and
Table 4. Multivariable adjusted Hazard Ratios (95% confidence interval) of Atrial Fibrillation of a 1 Standard Deviation Increase in Non-pleiotropic
Lipid Gene Score, by Cohort. HR, Hazard Ratio; CI, Confidence interval; NA, not available. AGES, indicates the Age, Gene/Environment Susceptibility—
Reykjavik study; ARIC, Atherosclerosis Risk in Communities; FHS, Framingham Heart Study; MDCS, Malmö Diet and Cancer study; RS, Rotterdam Study;
WGHS,Women's Genome Health Study. Model 1: Cox proportional hazard model adjusted for age, sex and study center, if appropriate. Model 2: Model 1
+ education, height, smoking status, body mass index, systolic blood pressure, diastolic blood pressure, use of antihypertensive medication, diabetes, left
ventricular hypertrophy, previous stroke, previous coronary heart disease and previous heart failure. Model 3: Model 2 + adjusted for continuous lipid levels
and lipid medication use.
AGES ARIC FHS MDCS RS-I RS-II WGHS
HDLc non-pleiotropic gene score
Model 1: HR (95% CI) 0.93 (0.85–1.03) 1.02 (0.97–1.08) 1.01(0.94–1.10) 1.00 (0.96–1.05) 1.05 (0.96–1.14) 0.84 (0.68–1.04) 0.99 (0.90–1.08)
Model 2: HR (95% CI) 0.93 (0.84–1.02) 1.03 (0.97–1.09) 1.01(0.93–1.10) 0.99 (0.95–1.04) 1.04 (0.95–1.13) 0.86 (0.69–1.08) 0.99 (0.91–1.08)
Model 3: HR (95% CI) 0.93 (0.84–1.03) 1.03 (0.97–1.09) 1.01(0.91–1.12) 1.06 (0.96–1.17) 1.04 (0.95–1.13) 0.85 (0.68–1.07) 0.98 (0.90–1.08)
LDLc non-pleiotropic gene score
Model 1: HR (95% CI) 1.02 (0.93–1.13) 1.02 (0.96–1.08) 1.05(0.96–1.14) 1.02 (0.98–1.07) 0.93 (0.86–1.01) 1.03 (0.82–1.30) 1.02 (0.93–1.11)
Model 2: HR (95% CI) 1.02 (0.93–1.13) 1.02 (0.96–1.08) 1.04(0.95–1.13) 1.02 (0.97–1.06) 0.94 (0.87–1.02) 1.06 (0.84–1.33) 1.02 (0.93–1.11)
Model 3: HR (95% CI) 1.02 (0.92–1.12) 1.02 (0.96–1.08) 1.03(0.93–1.15) 1.04 (0.93–1.15) 0.96 (0.88–1.04) 1.06 (0.84–1.35) 1.03 (0.94–1.13)
doi:10.1371/journal.pone.0151932.t004
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triglycerides, and 6.8% of the variance in total cholesterol.[17] Therefore, it is unlikely that all
relevant lipid genes have been identified. A more recent list of lipid SNPs in 157 loci (62 new
loci in addition to the 95 used in the Teslovich study) was published after completion of data
analysis in all cohorts in our study. [34] We decided not to rerun our analysis for logistical rea-
sons, after considering the effect of the 62 new loci on lipid levels was generally smaller than in
the earlier GWAS (1.6–2.6% variance explained vs. 10–12% variance in the Teslovich loci), and
therefore, with our current analysis, we likely would have found an association if one existed.
Finally, our results may not be generalizable to nonwhites. Despite these limitations, our study
has important strengths including a large sample size, long follow-up, a large number of inci-
dent AF events, and an extensive list of measured covariates.
Conclusions
In conclusion, in our sample of approximately 65,000 white participants, lipid gene scores for
HDLc, LDLc, total cholesterol, and triglycerides were not associated with incident AF, meaning
we did not find a direct relationship between lipid levels and the risk of AF.
Fig 2. Meta-analysis of the association of non-pleiotropic HDLc and LDLc gene scores, and atrial fibrillation. Association is adjusted for age, sex,
center, education, height, smoking status, body mass index, systolic blood pressure, diastolic blood pressure, use of antihypertensive medication, diabetes,
left ventricular hypertrophy, previous stroke, previous coronary heart disease, and previous heart failure
doi:10.1371/journal.pone.0151932.g002
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